Last reviewed · How we verify

NCT04637789

The Whole Body Vibration for Sarcopenic Hospitalized Patients Aged 80+ Years

Completed NA Last updated 29 September 2021
What this trial tests

NA trial testing the whole body vibration in Sarcopenia in 60 participants. Completed in 27 September 2021.

Timeline
17 December 2020
Primary endpoint
1 September 2021
27 September 2021

Quick facts

Lead sponsorYuxiang Liang
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment60
Start date17 December 2020
Primary completion1 September 2021
Estimated completion27 September 2021
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Yuxiang Liang

Who can join

Adults 80 to 100, any sex, with Sarcopenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Resistance training have been recommended for sarcopenic patients. However, the whole body vibration training would further benefit for sarcopenic patients on the basis of resistance training remains unclear. The purpose of this study is to explore the effect of the whole body vibration training on improving the mobility of elderly patients with sarcopenia. The whole body vibration involves different frequencies that can improve muscle strength and keep aged upright, including the legs and core. These kinds of exercises can improve stability and help prevent falls.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Sarcopenia

Currently open trials in the same condition.

Other Yuxiang Liang trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04637789.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing